Request Demo
Last update 14 Jun 2025
BAT-1306
Last update 14 Jun 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms BAT 1306, BAT-1306 |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
6
Clinical Trials associated with BAT-1306NCT06111196
A Randomized, Double-blind, Single-dose, Three-arm Parallel Group, Phase I Study to Compare the Pharmacokinetics and Safety of BAT3306 Versus KEYTRUDA® Administered in Healthy Male Subjects
NCT04151329
Evaluation for the Safety of BAT1306 and BAT8001 Injection for the Treatment of Patients With HER2-positive Advanced Solid Tumors Phase I/IIa Clinical Trials of Sexual, Tolerability and Pharmacokinetic Characteristics
CTR20181775
一项评价BAT1306联合奥沙利铂和卡培他滨（XELOX）治疗EBV相关性胃癌患者的有效性和安全性的Ⅱ期临床试验
[Translation] A phase II clinical trial evaluating the efficacy and safety of BAT1306 combined with oxaliplatin and capecitabine (XELOX) in the treatment of patients with EBV-related gastric cancer
100 Clinical Results associated with BAT-1306
Login to view more data
100 Translational Medicine associated with BAT-1306
Login to view more data
100 Patents (Medical) associated with BAT-1306
Login to view more data
100 Deals associated with BAT-1306
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 21 Jun 2019 | |
| HER2 Positive Solid Tumors | Phase 2 | China | 21 Jun 2019 | |
| Epstein-Barr virus associated gastric carcinoma | Phase 2 | China | 08 Jan 2019 | |
| Bladder Cancer | Phase 1 | China | 04 Jan 2018 | |
| Head and Neck Neoplasms | Phase 1 | China | 04 Jan 2018 | |
| Kidney Neoplasms | Phase 1 | China | 04 Jan 2018 | |
| Melanoma | Phase 1 | China | 04 Jan 2018 | |
| Small Cell Lung Cancer | Phase 1 | China | 04 Jan 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free